TrialPloS one2019

Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.

Graham R Foster et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.